GlassScriptPhysician profile
Ekaterini Zapantis
NPI 1417249202
$219,870.32
in general payments reported to CMS, 2019-2025
39 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $21K · 2021: $12K · 2022: $13K · 2023: $40K · 2024: $36K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Food and Beverage: $16K · Travel and Lodging: $13K · Consulting Fee: $6,510 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,914.50 |
| Food and Beverage | $16,278.44 |
| Travel and Lodging | $13,121.42 |
| Consulting Fee | $6,510.00 |
| Education | $244.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $81,123.37 | 2019-2025 | |
| Pfizer INC. | $64,883.05 | 2019-2025 | |
| Amgen INC. | $25,264.06 | 2019-2025 | Tavneos, Otezla, Enbrel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,136.15 | 2019-2025 | Cyltezo, Ofev |
| Gilead Sciences, INC. | $8,720.66 | 2019-2020 | |
| Regeneron Pharmaceuticals, INC. | $6,611.73 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $4,226.20 | 2019 | |
| Abbvie INC. | $2,992.18 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $2,082.60 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $2,022.75 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $1,579.81 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,411.15 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $1,250.92 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $1,073.67 | 2019-2025 | Orencia, Sotyktu |
| Horizon Therapeutics Plc | $1,015.10 | 2019-2023 | Krystexxa |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $675.47 | 2019 | |
| Alexion Pharmaceuticals, INC. | $672.54 | 2019-2025 | Strensiq |
| Glaxosmithkline, LLC. | $631.40 | 2019-2025 | Benlysta |
| Sanofi-Aventis U.S. LLC | $550.68 | 2019-2024 | |
| Ani Pharmaceuticals, INC. | $542.58 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $431.92 | 2019 | |
| Sandoz INC. | $368.20 | 2023-2025 | Hyrimoz, Jubbonti |
| Lilly USA, LLC | $306.54 | 2019-2024 | Taltz, Olumiant |
| Janssen Scientific Affairs, LLC | $271.42 | 2022 | |
| Kyowa Kirin, INC. | $218.51 | 2024-2025 | Crysvita |
| Organon LLC | $134.24 | 2023-2024 | Hadlima, Renflexis |
| Genentech USA, INC. | $134.12 | 2019-2025 | Gazyva, Actemra |
| Genentech, INC. | $88.73 | 2019 | |
| Pacira Therapeutics, INC. | $74.99 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $65.77 | 2023-2025 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $64.88 | 2022-2024 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $47.03 | 2019 | |
| Scilex Pharmaceuticals INC. | $46.88 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $43.45 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $28.94 | 2024 | Arcalyst |
| Fresenius Kabi USA, LLC | $26.97 | 2025 | |
| Celltrion USA INC. | $20.12 | 2023 | Yuflyma |
| Octapharma USA, INC. | $16.57 | 2024 | Octagam Immune Globulin (Human) |
| Daiichi Sankyo INC. | $14.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ekaterini Zapantis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.